Neena Brizmohun
Deputy Editor
UK
36+ years of experience
Neena's other specialist areas include new medicines coming to market in the EU, clinical trials, post-marketing safety monitoring, transparency policies relating to the publication of trial data, and global harmonization initiatives for pharma and medtech.
A scientist by training, Neena started her journalistic career at Pharma Intelligence in 1997. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Scrip
By Neena Brizmohun 27 Nov 2020
With Novartis’s and Kite’s CAR T-cell therapies both expected to gain recommendations for pan-EU approval this week, discounts will need to be negotiated for these new treatments to reach the markets in Europe.
Topic Cell & Gene Therapy
Pink Sheet
By Neena Brizmohun 23 Nov 2020
Joining the international regulatory collaboration could become a key route for the UK to remain an early and priority market for global launches after the end of the Brexit transition period, says the industry group, BIA.
Topic Pharma-Brexit Brexit
Pink Sheet
By Neena Brizmohun 28 Aug 2020
The former industry executive and incoming MHRA chair says he wants to see the agency become an “enabler” in the UK health system. Meanwhile, the MHRA is still looking for a permanent chief executive after Ian Hudson stepped down from the post nearly a year ago.
Topic Regulation BioPharmaceutical
Pink Sheet
By Neena Brizmohun 07 Apr 2020
Recommendations from the European Medicines Agency explain the conditions under which early access to remdesivir could be given through compassionate use programs.
Topic Coronavirus
Pink Sheet
By Neena Brizmohun 02 Apr 2020
The regulatory agency also urges qualified persons at drug companies to let the agency know as soon as possible if they are finding that the new measures are not flexible enough to deal with the current logistical challenges quickly.
Topic Coronavirus Distribution
Pink Sheet
By Neena Brizmohun 09 Aug 2019
The stakes are extremely high for companies called before EU or US regulators and scientific experts to answer queries about their new drug applications at the later stages of the review process. How they perform is critical. Consultant Kate Dion has a raft of helpful tips for companies facing this daunting situation. Neena Brizmohun reports.
Topic Approvals
Pink Sheet
By Neena Brizmohun 06 Sep 2018
A new deal between Novartis and England’s National Health Service is one of the fastest funding approvals in the 70-year history of the NHS.
Topic Cancer
Pink Sheet
By Neena Brizmohun 08 Nov 2017
Novartis, having now submitted its CAR-T therapy CTL019 to the European Medicines Agency for approval.
Topic Drug Review
Medtech Insight
10 May 2016
Pink Sheet
07 Apr 2016
Pink Sheet
07 Apr 2016
Scrip
06 Apr 2016
Medtech Insight
30 Mar 2016
Medtech Insight
29 Mar 2016
Medtech Insight
21 Mar 2016
Pink Sheet
18 Mar 2016
Medtech Insight
17 Mar 2016
Medtech Insight
17 Mar 2016
Pink Sheet
14 Mar 2016
Pink Sheet
11 Mar 2016
Pink Sheet
09 Mar 2016
Medtech Insight
07 Mar 2016
Scrip
19 Feb 2016